Compare Live Nation Entertainment, Inc. (LYV) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Live Nation Entertainment, Inc. vs TransMedics Group Inc — how do they compare? Live Nation Entertainment, Inc. trades at $172.05 (market cap $39.92B), while TransMedics Group Inc trades at $77.34 (market cap $2.74B). The key difference: Live Nation Entertainment, Inc. is far larger — about 14.6× TransMedics Group Inc's market cap, and Live Nation Entertainment, Inc. is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Live Nation Entertainment, Inc. for 72 Days and TransMedics Group Inc for 24 Days on average.
| LYV | TMDX | |
|---|---|---|
Market Cap | $39.92B | $2.74B |
Volume | 1,982,609 | 949,331 |
Sector | Media | Health |
52-Week High | $188.46 | $150.42 |
52-Week Low | $125.61 | $61.99 |
Typical Hold Time | 72 Days | 24 Days |
Enterprise Value | $42.13B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Live Nation Entertainment (LYV) trades at $170.84, down 0.55% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 earnings beat with 1.05 EPS versus 0.66 expected, though Q1 and Q4 2025 missed estimates. Revenue growth continues with $25.2B in 2025, while net income margin remains thin at 0.51%. Analyst consensus is strongly bullish with 87% buy ratings and a $208.18 price target, representing 22% upside potential.
LYV benefits from strong consumer demand for live events ('funflation' trend) and record deferred revenue of $6.4B, but faces execution risks from cost pressures, legal uncertainties, and high debt levels. The stock's elevated P/E of 117.5 reflects growth expectations, making it sensitive to earnings delivery. Near-term support sits at $169 with resistance at $172.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
